Angel Adegbesan

New York

Reporter at Bloomberg News

Stocks reporter @business. Alum at @newmarkjschool and @yorkcollegecuny

Featured in: Favicon

bloomberg.com Favicon

washingtonpost.com Favicon

time.com

yahoo.com (+10) Favicon

latimes.com Favicon

smh.com.au Favicon

chicagotribune.com Favicon

ndtv.com

thestar.com Favicon

chron.com + 87 more

Articles

Caris Life Sciences Shares Climb After $494 Million IPO

1 week ago | bloomberg.com | Angel Adegbesan |Anthony Hughes

(Bloomberg) -- Caris Life Sciences Inc. jumped 33% after the health-care company raised $494 million in a US initial public offering that priced above the top of its marketed range. Shares of the Sixth Street Partners-backed firm, which uses technology to help diagnose and treat cancer, closed at $28 each on Wednesday in New York, versus an IPO price of $21 apiece. Caris sold 23.5 million shares in the IPO after offering them for $19 to $20 each, in a range that had already been increased.
Caris Life Sciences IPO Prices Above Range to Raise $494 Million

1 week ago | bloomberg.com | Angel Adegbesan |Anthony Hughes

(Bloomberg) -- Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million in a US initial public offering that priced above the top of its marketed range. The Sixth Street Partners-backed company sold 23.5 million shares at $21 each, according to a statement Tuesday. The medical technology firm had offered shares for $19 to $20 each, above a previous proposed range of $16 to $18, an earlier filing showed.
Caris Life Sciences IPO Prices Above Range to Raise $494 Million

1 week ago | news.bloomberglaw.com | Angel Adegbesan |Anthony Hughes

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million in a US initial public offering that priced above the top of its marketed range. The Sixth Street Partners-backed company sold 23.5 million shares at $21 each, according to a statement Tuesday. The medical technology firm had offered shares for $19 to $20 each, above a previous proposed range of $16 to $18, an earlier filing showed.
The company with zero revenue that is worth $31 billion

1 week ago | smh.com.au | Angel Adegbesan

By Angel Adegbesan June 17, 2025 — 7.30pm, register or subscribe to save articles for later. Add articles to your saved list and come back to them any time. A biotech stock focused on herbal medicine has surged by more than 64,000 per cent so far this year, although the company has made zero revenue, much less turned a profit.
Herbal Medicine Stock With No Sales Sees Rally Top 46,000% (1)

1 week ago | news.bloomberglaw.com | Angel Adegbesan

A biotech stock focused on herbal medicine has surged by more than 46,000% so far this year and yet, the company itself has made zero revenue — much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth nearly $30 billion in market value. A year ago, the stock had a market capitalization of just $53 million.
Herbal Medicine Stock With No Sales Rallies 64,000%

1 week ago | bloomberg.com | Angel Adegbesan

(Bloomberg) -- A biotech stock focused on herbal medicine has surged by more than 46,000% so far this year and yet, the company itself has made zero revenue — much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth nearly $30 billion in market value. A year ago, the stock had a market capitalization of just $53 million.
Revelation-Backed Omada Health Jumps After $150 Million IPO

3 weeks ago | ca.finance.yahoo.com | Angel Adegbesan |Anthony Hughes

(Bloomberg) -- Omada Health Inc. shares ended their debut trading day exactly where they started after the digital health-care company raised $150 million in its initial public offering. • ICE Moves to DNA-Test Families Targeted for Deportation with New Contract• Where Public Transit Systems Are Bouncing Back Around the World• US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn• Trump Said He Fired the National Portrait Gallery Director. She’s Still There.
Revelation-Backed Omada Health Jumps After $150 Million IPO

3 weeks ago | bloomberg.com | Angel Adegbesan |Anthony Hughes

A Wall Street sign near the New York Stock Exchange (NYSE) in New York, US, on Thursday, May 22, 2025. A surge in long-term bond yields is once again threatening to upend a crowded hedge-fund bet that Treasuries will perform better than interest-rate swaps. Photographer: Michael Nagle/Bloomberg(Bloomberg) -- Omada Health Inc. shares ended their debut trading day exactly where they started after the digital health-care company raised $150 million in its initial public offering.
Omada Health IPO Raises $150 Million Priced in Middle of Range

3 weeks ago | bloomberg.com | Angel Adegbesan

(Bloomberg) -- Omada Health Inc.’s initial public offering raised $150 million, with shares of the digital health-care company pricing in the middle of the marketed range. The firm sold 7.9 million shares at $19 each, according to a statement Thursday. The San Francisco-based company had offered 7.9 million shares each at $18 to $20 apiece, a filing with the US Securities and Exchange Commission showed.
Halozyme Shares Dip as Wells Fargo Flags Review in Patent Case

3 weeks ago | news.bloomberglaw.com | Angel Adegbesan

shares slip as much as 2.9% after Wells Fargo said the Patent Trial and Appeal Board has instituted a patent grant review (PGR) against the company amid an with • The institution of the PGR likely reduces the probability of Halozyme prevailing in the patent infringement case, analyst writes in a note to clients • Halozyme winning the infringement suit is a “bull case” that is often noted as a potential source of upside • “Institution of MRK’s PGR lowers the probability of this bull case” •...